Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

IGF-II induces CREB phosphorylation and cell survival in human lung cancer cells

Oncogene volume 24, pages 7310–7319 (2005)Cite this article

Abstract

We have previously shown that lung tumors arising in MMTV-IGF-II transgenic mice displayed elevated levels of phosphorylated cAMP response element binding protein (CREB). To investigate the role that insulin-like growth factor II (IGF-II) and CREB play in human lung tumorigenesis, A549 and NCI-H358 cells were examined. In these cell lines, IGF-II administration enhances human tumor cell survival and CREB phosphorylation. Further, the effects of IGF-II on cell survival and CREB phosphorylation appeared to be mediated, at least in part, by activation of the Erk pathways, as inhibition of these signaling pathways reduced tumor cell survival and CREB phosphorylation. Specifically, Erk5 appeared as the predominant mediator of CREB phosporylation. To further verify the importance of CREB in human lung tumorigenesis, A549 and NCI-H358 cells were stably transfected with a vector containing a dominant negative CREB construct (KCREB). KCREB transfection significantly inhibited the soft agar growth of both human tumor cell lines. In contrast, overexpression of wild-type CREB in the normal human bronchial epithelial cell line, HBE135, enhanced soft agar growth. Therefore, our results indicate that CREB and its associated proteins play a significant role in lung adenocarcinoma and IGF-II induces CREB phosphorylation, at least in part, via the Erk5 signaling pathway.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  • Adams JM and Cory S . (1998). Science, 281, 1322–1326.

  • Adams TE, Epa VC, Garrett TP and Ward CW . (2000). Cell Mol. Life Sci., 57, 1050–1093.

  • Alvarez-Lopez C, Cernuda-Cernuda R, Paniagua MA, Alvarez-Viejo M, Fernandez-Lopez A and Garcia-Fernandez JM . (2004). Neurosci. Lett., 357, 223–226.

  • Arteaga CL and Holt JT . (1996). Cancer Res., 56, 1098–1103.

  • Baserga R . (1999). Exp. Cell Res., 253, 1–6.

  • Botas C, Poulain F, Akiyama J, Brown C, Allen L, Goerke J, Clements J, Carlson E, Gillespie AM, Epstein C and Hawgood S . (1998). Proc. Natl. Acad. Sci. USA, 95, 11869–11874.

  • Bourtchuladze R, Frenguelli B, Blendy J, Cioffi D, Schutz G and Silva AJ . (1994). Cell, 79, 59–68.

  • Dong L, Wang W, Wang F, Stoner M, Reed JC, Harigai M, Samudio I, Kladde MP, Vyhlidal C and Safe S . (1999). J. Biol. Chem., 274, 32099–32107.

  • Fowden AL . (2003). Placenta, 24, 803–812.

  • Ginty DD, Kornhauser JM, Thompson MA, Bading H, Mayo KE, Takahashi JS and Greenberg ME . (1993). Science, 260, 238–241.

  • Gonzalez GA, Yamamoto KK, Fischer WH, Karr D, Menzel P, Biggs III W, Vale WW and Montminy MR . (1989). Nature, 337, 749–752.

  • Grothey A, Voigt W, Schober C, Muller T, Dempke W and Schmoll HJ . (1999). J. Cancer Res. Clin. Oncol., 125, 166–173.

  • Habener JF, Vallejo M and Hoeffler JP . (1989). Horm. Res., 32, 61–66.

  • Hagiwara M, Alberts A, Brindle P, Meinkoth J, Feramisco J, Deng T, Karin M, Shenolikar S and Montminy M . (1992). Cell, 70, 105–113.

  • Jean D and Bar-Eli M . (2000). Mol. Cell Biochem., 212, 19–28.

  • Jean D, Harbison M, McConkey DJ, Ronai Z and Bar-Eli M . (1998). J. Biol. Chem., 273, 24884–24890.

  • Jiang Y, Rom WN, Yie TA, Chi CX and Tchou-Wong KM . (1999). Oncogene, 18, 6071–6077.

  • Jochum W, Passegue E and Wagner EF . (2001). Oncogene, 20, 2401–2412.

  • Kelemen BR, Hsiao K and Goueli SA . (2002). J. Biol. Chem., 277, 8741–8748.

  • Khachigian LM and Collins T . (1998). J. Mol. Med., 76, 613–616.

  • Liu W, Liu Y and Lowe Jr WL . (2001). Endocrinology, 142, 1710–1719.

  • Luciani P, Buci L, Conforti B, Tonacchera M, Agretti P, Elisei R, Vivaldi A, Cioppi F, Biliotti G, Manca G, Vitti P, Serio M and Peri A . (2003). Eur. J. Endocrinol., 148, 579–586.

  • Malkinson AM . (1991). Environ. Health Perspect., 93, 149–159.

  • Moorehead RA, Fata JE, Johnson MB and Khokha R . (2001). Cell Death Diff., 8, 16–29.

  • Moorehead RA, Sanchez OH, Baldwin RM and Khokha R . (2003). Oncogene, 22, 853–857.

  • Nakanishi Y, Mulshine JL, Kasprzyk PG, Natale RB, Maneckjee R, Avis I, Treston AM, Gazdar AF, Minna JD and Cuttitta F . (1988). J. Clin. Invest., 82, 354–359.

  • Ofir R, Dwarki VJ, Rashid D and Verma IM . (1991). Gene Experiment, 1, 55–60.

  • Pavelic J, Pavelic L, Karadza J, Krizanac S, Unesic J, Spaventi S and Pavelic K . (2002). Mol. Med., 8, 149–157.

  • Pavelic K, Pavelic ZP, Cabrijan T, Karner I, Samarzija M and Stambrook PJ . (1999). J. Pathol., 188, 69–75.

  • Peri A, Luciani P, Tonacchera M, Agretti P, Baglioni-Peri S, Buci L, Conforti B, Cioppi F, Biliotti G, Serio M, Vitti P and Chiovato L . (2002). Eur. J. Endocrinol., 146, 759–766.

  • Perissi V, Dasen JS, Kurokawa R, Wang Z, Korzus E, Rose DW, Glass CK and Rosenfeld MG . (1999). Proc. Natl. Acad. Sci. USA, 96, 3652–3657.

  • Petrich BG and Wang Y . (2004). Trends Cardiovasc. Med., 14, 50–55.

  • Quinn KA, Treston AM, Unsworth EJ, Miller MJ, Vos M, Grimley C, Battey J, Mulshine JL and Cuttitta F . (1996). J. Biol. Chem., 271, 11477–11483.

  • Rabelo FL, Ropert C, Ramos MG, Bonjardim CA, Gazzinelli RT and Alvarez-Leite JI . (2003). Biochem. Biophys. Res. Commun., 303, 968–972.

  • Reddy SPM, Adiseshaiah P, Shapiro P and Vuong H . (2002). Am. J. Respir. Cell Mol. Biol., 27, 64–70.

  • Reeve JG, Brinkman A, Hughes S, Mitchell J, Schwander J and Bleehen NM . (1992). J. Natl. Cancer Inst., 84, 628–634.

  • Reeve JG, Morgan J, Schwander J and Bleehen NM . (1993). Cancer Res., 53, 4680–4685.

  • Rehm S, Devor DE, Henneman JR and Ward JM . (1991). Exp. Lung Res., 17, 181–195.

  • Rosenberg D, Groussin L, Bertagna X and Bertherat J . (2002a). Endocr. Res., 28, 765–775.

  • Rosenberg D, Groussin L, Jullian E, Perlemoine K, Bertagna X and Bertherat J . (2002b). Ann. NY Acad. Sci., 968, 65–74.

  • Rotsch M, Maasberg M, Erbil C, Jaques G, Worsch U and Havemann K . (1992). J. Cancer Res. Clin. Oncol., 118, 502–508.

  • Rubin R and Baserga R . (1995). Lab. Invest., 73, 311–331.

  • Rubini M, D’Ambrosio C, Carturan S, Yumet G, Catalano E, Shan S, Huang Z, Criscuolo M, Pifferi M and Baserga R . (1999). Exp. Cell Res., 251, 22–32.

  • Saeki K, Yuo A, Koizumi M, Fujiwara K, Kaneko M, Takaku F and Yazaki Y . (2001). Leukemia, 15, 238–245.

  • Sakamoto KM, Fraser JK, Lee HJ, Lehman E and Gasson JC . (1994). Mol. Cell. Biol., 14, 5975–5985.

  • Scapoli L, Ramos-Nino ME, Martinelli M and Mossman BT . (2004). Oncogene, 23, 805–813.

  • Shankar DB and Sakamoto KM . (2004). Leuk. Lymphoma, 45, 265–270.

  • Shaywitz AJ and Greenberg ME . (1999). Annu. Rev. Biochem., 68, 821–861.

  • Sung JY, Shin SW, Ahn YS and Chung KC . (2001). J. Biol. Chem., 276, 13858–13866.

  • Surmacz E, Guvakova MA, Nolan MK, Nicosia RF and Sciacca L . (1998). Breast Cancer Res. Treat., 47, 255–267.

  • Takanami I, Imamuma T, Hashizume T, Kikuchi K, Yamamoto Y, Yamamoto T and Kodaira S . (1996). J. Surg. Oncol., 61, 205–208.

  • Thiel G and Cibelli G . (2002). J. Cell Physiol., 193, 287–292.

  • Valentinis B and Baserga R . (2001). Mol. Pathol., 54, 133–137.

  • Wada T and Penninger JM . (2004). Oncogene, 23, 2838–2849.

  • Watson FL, Heerssen HM, Bhattacharyya A, Kleese L, Lin MZ and Segal RA . (2001). Nat. Neurosci., 4, 981–988.

  • Xie S, Price JE, Luca M, Jean D, Ronai Z and Bar-Eli M . (1997). Oncogene, 15, 2069–2075.

  • Yan SF, Pinsky DJ, Mackman N and Stern DM . (2000). J. Clin. Invest., 105, 553–554.

  • Yoshida K, Imaki J, Matsuda H and Hagiwara M . (1995). J. Neurochem., 65, 1499–1504.

Download references

Acknowledgements

This work was funded by an Operating Grant from the Canadian Institutes of Health Research and an Equipment Grant from the Canadian Foundation for Innovation.

Author information

Authors and Affiliations

  1. Department of Biomedical Sciences, Ontario Veterinary College, University of Guelph, Guelph, ON, Canada, N1G2W1

    Nicolle M Linnerth, Mitch Baldwin, Craig Campbell, Melissa Brown, Heather McGowan & Roger A Moorehead

Authors
  1. Nicolle M Linnerth
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mitch Baldwin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Craig Campbell
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Melissa Brown
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Heather McGowan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Roger A Moorehead
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Roger A Moorehead.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Linnerth, N., Baldwin, M., Campbell, C. et al. IGF-II induces CREB phosphorylation and cell survival in human lung cancer cells. Oncogene 24, 7310–7319 (2005). https://doi.org/10.1038/sj.onc.1208882

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1208882

Keywords

This article is cited by

Search

Advanced search

Quick links